Previous 10 | Next 10 |
2023-08-11 08:47:18 ET Cel-Sci press release ( NYSE: CVM ): Q2 GAAP EPS of -$0.19. For further details see: Cel-Sci GAAP EPS of -$0.57
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments. Clinical and Corporate Developments this quarter include: CEL-SCI had a productive pre-submission meeting with Canada...
2023-07-25 11:16:57 ET Summary Cel-Sci is struggling to commercialize its Multikine cancer therapy; it recently closed on a small but expensive financing. The company has completed its initial end of phase 3 meeting with the FDA; it issued an inconclusive report. Cel-Sci is a ...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share,...
2023-07-18 10:13:56 ET Gainers: iCAD ( ICAD ) +31% . Biophytis ( BPTS ) +27% . Hyperfine ( HYPR ) +15% . Cabaletta Bio ( VERU ) +12% . Mind Medicine (MindMed) ( MNMD ) +10% . Losers: Lixte Biotechnology ( LIXT ) ...
2023-07-18 05:30:30 ET Stock futures rose slightly as investors awaited U.S. retail sales data to shed light on the Federal Reserve's policy outlook. Here are some of Tuesday's biggest stock gainers and losers: Biggest stock gainers For further details see: Biggest stock mov...
2023-07-18 01:25:22 ET CEL-SCI ( NYSE: CVM ) has priced an underwritten public offering of 2.5 million shares of its common stock at a public offering price of $2.00/share, for gross proceeds of $5 million. The stock was down 18.9% at $2.32 after-hours on Mo...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM) , a Phase 3 cancer immunotherapy company, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $2.00 per share, for...
2023-07-17 16:34:19 ET CEL-SCI ( NYSE: CVM ) plans to offer to sell shares of its common stock in an underwritten public offering, the company said Monday. Shares of the company -24% at $2.15 after hours. The underwriter has a 45-day option to purchase up to ...
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. The Company expects to grant the under...
News, Short Squeeze, Breakout and More Instantly...
CEL-SCI Corporation (NYSE American: CVM) today announced that Robert (“Bob”) Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. Wi...
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant log rank p = 0.0015 ...
Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cut...